A European Post-Authorisation Observational Study Of Patients With Hereditary Angioedema
A European Post-Authorisation Observational Study Of Patients With Hereditary Angioedema
This observational (non-interventional) study is being conducted to characterize the safety
 and use of CINRYZE in routine clinical practice when administered for (1) routine prevention
 of angioedema attacks, (2) pre-procedure prevention of angioedema attacks, and/or (3)
 treatment of angioedema attacks.
Inclusion Criteria

 All patients must:

 -  Have a diagnosis of HAE and be receiving CINRYZE for prevention or treatment of
 angioedema attacks

 -  Provide written informed consent/assent in compliance with applicable country-specific
 and local regulations

 Exclusion Criteria

 All patients must not:

 -  Be receiving CINRYZE in an investigational study

 -  Be receiving another HAE therapy as part of a clinical trial